A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa

Summary

Efficacy and safety of imsidolimab (ANB019) in participants with Hidradenitis Suppurativa

Timeline

Start

2021-07-07

Primary completion

2022-07-15

Completion

2022-12-14

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo-Controlled Period: Imsidolimab 400/200 mg vs Placebo-Controlled Period: Placebo; p = 0.7841; NCT04856930 ↗

registry analysis (superiority test); Placebo-Controlled Period: Imsidolimab 200/100 mg vs Placebo-Controlled Period: Placebo; p = 0.2885; NCT04856930 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Imsidolimab	Monoclonal antibody	100 mg	Subcutaneous
Subject	Imsidolimab	Monoclonal antibody	200 mg	Subcutaneous

Indications